965 related articles for article (PubMed ID: 27240826)
21. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
23. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
24. Identification of key regulators of pancreatic ductal adenocarcinoma using bioinformatics analysis of microarray data.
Li N; Zhao X; You S
Medicine (Baltimore); 2019 Jan; 98(2):e14074. PubMed ID: 30633213
[TBL] [Abstract][Full Text] [Related]
25. Analysis of molecular pathways in pancreatic ductal adenocarcinomas with a bioinformatics approach.
Wang Y; Li Y
Asian Pac J Cancer Prev; 2015; 16(6):2561-7. PubMed ID: 25824797
[TBL] [Abstract][Full Text] [Related]
26. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
27. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
28. Identification of hub genes and analysis of prognostic values in pancreatic ductal adenocarcinoma by integrated bioinformatics methods.
Lu Y; Li C; Chen H; Zhong W
Mol Biol Rep; 2018 Dec; 45(6):1799-1807. PubMed ID: 30173393
[TBL] [Abstract][Full Text] [Related]
29. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
30. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
31. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma.
Gardi N; Ketkar M; McKinnon RA; Pandol SJ; Dutt S; Barreto SG
ANZ J Surg; 2021 Nov; 91(11):2466-2474. PubMed ID: 34514690
[TBL] [Abstract][Full Text] [Related]
33. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
Tan Z; Lei Y; Xu J; Shi S; Hua J; Zhang B; Meng Q; Liu J; Zhang Y; Wei M; Yu X; Liang C
Aging (Albany NY); 2020 Nov; 12(23):24228-24241. PubMed ID: 33226369
[TBL] [Abstract][Full Text] [Related]
34. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
35. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
[TBL] [Abstract][Full Text] [Related]
36. Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.
Wu Y; Wei J; Ming Y; Chen Z; Yu J; Mao R; Chen H; Zhou G; Fan Y
J Cell Biochem; 2018 Sep; 119(9):7696-7706. PubMed ID: 29923223
[TBL] [Abstract][Full Text] [Related]
37. Integration of mRNA and protein expression data for the identification of potential biomarkers associated with pancreatic ductal adenocarcinoma.
Akrami S; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
Comput Biol Med; 2023 May; 157():106529. PubMed ID: 36921457
[TBL] [Abstract][Full Text] [Related]
38. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma.
Xiao Y
J Cell Biochem; 2020 Jan; 121(1):394-406. PubMed ID: 31232492
[TBL] [Abstract][Full Text] [Related]
39. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma.
Hao S; Yao L; Huang J; He H; Yang F; Di Y; Jin C; Fu D
Technol Cancer Res Treat; 2018 Jan; 17():1533034617748429. PubMed ID: 29343207
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.
Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y
Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
